Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection
European Journal of Surgical Oncology · 2026
DOI: 10.1016/j.ejso.2025.111167 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Yanzhao Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Electronic Science and Technology of China, Chengdu, 611731, China; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Henan Provincial Science and Technology Research Project, Henan Medical Science and Technique Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Early detection is crucial for improving the overall survival rates in patients diagnosed with HCC. MATERIALS AND METHODS: In this study, we developed a novel methylation-based gene panel for HCC detection using a large cohort of 149 patients with HCC and 270 controls, which included 109 healthy individuals, 102 patients with benign liver diseases, and 59 patients with non-hepatic malignancies. The diagnostic performance of the panel was assessed by generating receiver operating characteristic (ROC) curves to determine the area under the curve (AUC), sensitivity, specificity, and corresponding 95 % confidence intervals (CIs). All statistical figures were generated using GraphPad Prism software. RESULTS: Our analysis revealed significantly elevated methylation levels of SEPTIN9, Suppressor of Cytokine Signaling 1 (SOCS1), and Cyclooxygenase-2 (COX2) in HCC patients compared to those in all control groups. The panel demonstrated strong diagnostic performance, achieving an AUC of 0.907 (95 % CI: 0.876-0.933), with a sensitivity of 83.9 % (95 % CI: 77.0-89.4 %) and a specificity of 88.5 % (95 % CI: 84.1-92.1 %). Importantly, it exhibited high diagnostic efficacy for early stage HCC, achieving sensitivities of 75.0 % for stage I and 84.0 % for stage II. Comparisons with pathological findings yielded a kappa value of 0.72, indicating a substantial agreement with the gold standard. CONCLUSION: These findings suggest that the DNA methylation biomarkers panel could revolutionize HCC diagnostics by enabling earlier, more accurate, and cost-effective detection, particularly in high-risk populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Electronic Science and Technology of China, Chengdu, 611731, China; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zheng…
- Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
- Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China; Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450008, China.
- Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China; Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450008, China. Electro…
- Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Electronic address: zhoujx888@126.com.
Förderung
- Henan Provincial Science and Technology Research Project
- Henan Medical Science and Technique Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Zhang, B., Yang, K., Wang, Z., Li, Q., Wang, W., Chen, D., Ma, J., & Zhou, J. (2026). Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111167
Vancouver
Zhou Y, Zhang B, Yang K, Wang Z, Li Q, Wang W, et al. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111167
BibTeX
@article{Zhou2026,
author = {Zhou, Yanzhao and Zhang, Beilin and Yang, Ke and Wang, Zhengzheng and Li, Qingjun and Wang, Weizhen and Chen, Dongxu and Ma, Jie and Zhou, Jinxue},
title = {Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection},
journal = {European Journal of Surgical Oncology},
year = {2026},
doi = {10.1016/j.ejso.2025.111167}
}
EUVIMED